Avidity Biosciences Inc
$ 72.80
0.00%
26 Feb - close price
- Market Cap 11,246,062,000 USD
- Current Price $ 72.80
- High / Low $ 72.80 / 72.80
- Stock P/E N/A
- Book Value 11.17
- EPS -4.19
- Next Earning Report 2026-02-26
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.26 %
- ROE -0.44 %
- 52 Week High 73.06
- 52 Week Low 21.51
About
Avidity Biosciences, Inc., a biopharmaceutical company, is dedicated to the development of oligonucleotide-based therapies. The company is headquartered in La Jolla, California.
Analyst Target Price
$74.64
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-10 | 2025-08-07 | 2025-05-07 | 2025-02-26 | 2024-11-06 | 2024-08-09 | 2024-05-09 | 2024-02-28 | 2023-11-08 | 2023-08-08 | 2023-05-09 | 2023-02-28 |
| Reported EPS | -1.27 | -1.21 | -0.9 | -0.8 | -0.65 | -0.65 | -0.79 | -0.79 | -0.71 | -0.66 | -0.74 | -0.88 |
| Estimated EPS | -1.14 | -0.9562 | -0.8803 | -0.7809 | -0.71 | -0.79 | -0.78 | -0.66 | -0.77 | -0.8 | -0.85 | -0.89 |
| Surprise | -0.13 | -0.2538 | -0.0197 | -0.0191 | 0.06 | 0.14 | -0.01 | -0.13 | 0.06 | 0.14 | 0.11 | 0.01 |
| Surprise Percentage | -11.4035% | -26.5426% | -2.2379% | -2.4459% | 8.4507% | 17.7215% | -1.2821% | -19.697% | 7.7922% | 17.5% | 12.9412% | 1.1236% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-26 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -1.24 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: RNA
2026-02-25 00:54:29
Avidity Biosciences (RNA) reported a net loss of US$237.1 million for FY 2025, bringing its trailing 12-month net loss to US$684.6 million against total revenue of US$18.8 million. While analysts forecast 51.4% annual revenue growth, challenging the current loss-making trend, critics point to expanding losses and a P/B ratio higher than the industry average. Despite a significant DCF fair value indicating undervaluation, the company faces skepticism regarding its path to profitability and shareholder dilution.
2026-02-23 20:56:50
Avidity Biosciences, Inc. has released its Form 10-K report for the fiscal year ended December 31, 2025, detailing financial performance, business operations, and strategic initiatives. The report highlights the company's focus on developing Antibody Oligonucleotide Conjugates (AOCs) for rare diseases, significant R&D expenses, and a planned merger with Novartis AG. Challenges include merger uncertainty, ongoing operating losses, and risks associated with manufacturing and market conditions.
2026-02-23 20:22:30
Avidity Biosciences announced it will adjourn its Special Meeting of Stockholders on February 23, 2026, and reconvene it on February 26, 2026. This adjournment is to allow more time to fulfill conditions for the pro rata distribution of Atrium Therapeutics, Inc. common stock to Avidity stockholders, which is a prerequisite for its proposed merger with Novartis AG. The distribution is expected on February 26, 2026, and the merger closing on February 27, 2026, with Avidity's common stock temporarily trading as "RNAM" during the distribution.
2026-02-23 17:19:47
Avidity Biosciences announced its plan to adjourn its special stockholders meeting scheduled for February 23, 2026, and reconvene it on February 26, 2026. This adjournment is intended to allow more time to satisfy conditions for the pro rata distribution of Atrium Therapeutics shares, which is a precursor to Avidity's proposed merger with Novartis AG. The Distribution is now expected on February 26, 2026, with the merger closing on February 27, 2026, both subject to closing conditions including stockholder approval.
2026-02-23 14:19:47
Avidity Biosciences, Inc. (RNA) is a biopharmaceutical company demonstrating significant growth, with a 434% revenue surge and an $11.26 billion market capitalization. The company is advancing several RNA therapeutic programs through clinical trials for diseases like myotonic dystrophy type 1 and muscular dystrophies. Despite substantial investment in its pipeline leading to negative EPS and free cash flow, analyst sentiment indicates cautious optimism for its long-term potential in biotechnology.
2026-02-23 13:44:57
Avidity Biosciences will adjourn its special meeting scheduled for February 23rd, 2026, and reconvene on February 26th, 2026. This adjournment is to allow more time for the completion of the SpinCo distribution. The company expects the distribution to occur on February 26th, 2026, with the merger with Novartis closing the following day, February 27th, 2026, pending closing conditions.
